Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.

[1]  B. Olaisen,et al.  Interactions of membrane stabilizing drugs affecting human erythrocytes in vitro. , 1973, European journal of pharmacology.

[2]  W. Frishman,et al.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applications. , 1979, American heart journal.

[3]  W. Ritschel.  Compilation of Pharmacokinetic Parameters of Beta-Adrenergic Blocking Agents , 1980 .

[4]  W. Frishman,et al.  β-Adrenoceptor Antagonists: New Drugs and New Indications , 1981 .

[5]  W. G. Anderson,et al.  Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function. , 1982, Journal of medicinal chemistry.

[6]  W. G. Anderson,et al.  Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent. , 1982, Journal of medicinal chemistry.

[7]  W. G. Anderson,et al.  Ultra-short acting beta-blockers: a proposal for the treatment of the critically ill patient. , 1982, Life sciences.

[8]  E. Braunwald,et al.  First ultra-short-acting beta-adrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs. , 1983, The American journal of cardiology.

[9]  R. Vollmer,et al.  Cardiovascular pharmacology of ASL-8052, an ultra-short acting β blocker , 1983 .

[10]  A. Yacobi,et al.  Kinetics of esmolol, an ultra‐short‐acting beta blocker, and of its major metabolite , 1983, Clinical pharmacology and therapeutics.

[11]  R. Lee,et al.  Pharmacology of ASL‐8052, a Novel β-Adrenergic Receptor Antagonist with an Ultrashort Duration of Action , 1983, Journal of cardiovascular pharmacology.

[12]  K. Swedberg,et al.  The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. , 1983, Circulation.

[13]  G. Ferrier,et al.  Contribution of Variable Entrance and Exit Block in Protected Foci to Arrhythmogenesis in Isolated Ventricular Tissues , 1983, Circulation.

[14]  J. Reves,et al.  ATTENUATION OF HEART RATE RESPONSE TO INTUBATION BY A NEW BETA-ADRENERGIC BLOCKING DRUG, ESMOLOL , 1984 .

[15]  M. Gold,et al.  THE EFFECT OF ESMOLOL ON HEMODYNAMICS AFTER KETAMINE INDUCTION AND INTUBATION , 1984 .

[16]  R. Sung,et al.  Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. , 1984, Journal of the American College of Cardiology.

[17]  B. Covino,et al.  EVALUATION OF ACUTE CARDIOVASCULAR EFFECTS OF ESMOLOL IN THE DOG–AWAKE AND ANESTHETIZED WITH HALOTHANE AND ENFLURANE , 1984 .

[18]  T. Bateman,et al.  Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. , 1985, Journal of the American College of Cardiology.